Stem Cell

GSK, Plasticell Partner to Produce Hematopoietic Cells from iPSCs

  • GlaxoSmithKline (GSK) will provide combinations of molecules for screening through Plasticell’s Combinatorial Cell Culture™ (CombiCult®) combinatorial stem cell screening technology, through a collaboration whose value was not disclosed.

    Plasticell will use the bead-based CombiCult platform to produce hematopoietic cells from induced pluripotent stem cells (iPSCs) by optimizing the directed differentiation of the iPSCs to specific blood cell lineages for use by GSK in therapeutic research, the companies said.

    CombiCult is designed to allow for simultaneous screening of multiple iPSC lines, facilitating the development of a robust protocol that is applicable across lines, Plasticell added.

    “During the course of developing its therapeutic programs, Plasticell has acquired considerable expertise in pluripotent and hematopoietic stem cells, the derivation of specific hematopoietic cell types, and the use of small molecules to drive stem…